Bladder Cancer

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Vote on the latest breakthroughs in renal and bladder cancer at ESMO 2025, featuring pivotal late-breaking abstracts.

Explore the latest advancements in muscle-invasive bladder cancer treatment, including immunotherapy and novel therapies enhancing patient outcomes.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive bladder cancer patients ineligible for cisplatin.

Sam S. Chang MD, MBA, discusses intravesical mitomycin in low-grade intermediate-risk nonmuscle-invasive bladder cancer vs different treatment paths.

Sam S. Chang MD, MBA, discusses the findings for mitomycin in for low-grade intermediate-risk nonmuscle-invasive bladder cancer.

During a live event, Matthew Galsky, MD, discussed adjuvant and neoadjuvant treatment approaches for muscle-invasive bladder cancer.

The ANZUP 1301 trial showed that BCG and mitomycin showed similar DFS to BCG alone in NMIBC, but with 40% fewer BCG doses and similar safety.

A phase 1b trial plans to evaluate AKY-1189 for the treatment of Nectin-4–expressing tumors.

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk NMIBC.

Roger Li, MD, discusses the MoonRISe-1 study evaluating TAR-210 in FGFR-altered intermediate-risk non-muscle-invasive bladder cancer.

Colin P.N. Dinney, MD, PhD, discussed updated analyses of the BOND-003 and CORE-001 trials in bladder cancer.

Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.

Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the POTOMAC trial.

Felix Guerrero-Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.

Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.

A phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.

Mark D. Tyson, MD, MPH, discusses cretostimogene and how it varies from other therapies for bladder cancer.

Mark Tyson, MD, MPH, discusses practice-changing data from the phase 3 BOND-003 study.

ENVISION trial 18-month data show UGN-102 yielded a high initial complete response (79.6%) in recurrent low-grade intermediate-risk NMIBC, with 80.6% maintaining response. The gel formulation with mitomycin offers a nonsurgical chemoablation with favorable tolerability.

Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk NMIBC with CIS. The 12-month CR rate was 45.9%, with durable responses and manageable safety. An FDA application is under review.

TAR-200 showed durable disease-free survival in high-risk, BCG-unresponsive papillary NMIBC in SunRISe-1, with high 6/9-month DFS rates and a low cystectomy rate.

Felix Guerrero-Ramos, MD, PhD, discusses findings from cohort 4 of the phase 2 SunRISe-1 trial of TAR-200 in patients with high-risk, BCG-unresponsive NMIBC with papillary-only disease.